IGFBP-2 vaccine to prevent ovarian cancer return
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a vaccine that targets a protein called IGFBP-2 to prevent ovarian cancer from coming back. It is for people whose CA-125 blood test shows the cancer might be returning, but who don't yet have tumors visible on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ovarian, fallopian tube, or primary peritoneal cancer and received chemotherapy with a platinum drug.
- Your CA-125 blood test has gone up to at least twice the normal level or twice your lowest level after the most recent treatment.
- You do not have any tumors that can be seen on a CT scan (fluid in the belly or around the lungs is okay if you don't have symptoms).
- You are at least 18 years old, have a life expectancy of at least 3 months, and are in good enough health to be up and about (ECOG score 0-1).
- Your blood counts, kidney function, and liver function are within certain safe limits, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy (a treatment that boosts your immune system) to surgery helps people whose ovarian cancer has returned and is sensitive to chemotherapy. It aims to see if this combination can improve outcomes for patients with certain biomarkers.
This Phase 2 trial studies a maintenance vaccine (DCVAC/OvCa) given after standard first-line chemotherapy and surgery for certain advanced ovarian cancers. It aims to help keep the cancer from coming back for longer by boosting the body’s anti-cancer response.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
Hear when a new Fallopian Tube Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.